Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

from The IMID Forum · host The Immune-Mediated Inflammatory Disease Forum

Join Dr Sofia Ramiro and Professor Atul Deodhar as they discuss the top publications in the world of axSpA. This month, the conversation covered how certolizumab pegol reduces anterior uveitis flares in high-risk axSpA and the effect of secukinumab dose escalation on MRI inflammation and damage in axSpA.

Episode metadata supplied by the publisher feed · Published May 15, 2026

Embed this episode

Attribution link and audio player

Ready to play

Discussing axSpA: Biologic therapy outcomes in axial spondyloarthritis

0:00 21:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The IMID Forum?

This episode is 21 minutes long.

When was this The IMID Forum episode published?

This episode was published on May 15, 2026.

Can I download this The IMID Forum episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!